CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
docetaxel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00242918
NCT00242918Phase 2Completed
CompareCT.gov

Phase II Trial of Neoadjuvant Docetaxel and ZD 1839 (Iressa) Followed by Radical Prostatectomy in Patients With High Risk, Locally Advanced Prostate Cancer

Benaroya Research Institute·interventional·Posted Oct 21, 2005·Updated Feb 7, 2012

In Brief

A Phase 2 clinical trial evaluating docetaxel and ZD1839 for Prostate Cancer. Completed, across 1 site.

Detailed Summary

The purpose of this study is to determine the safety and effectiveness of the combination of docetaxel and ZD1839 on destroying prostate cancer before removal of the prostate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsAstraZeneca, Sanofi

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 21, 2005
Enrollment StartMay 1, 2003
Study CompletionNov 1, 2007
TodayJul 2, 2026
Posted 20.7 years ago

Interventions

docetaxeldrug

ZD1839drug